loadpatents
name:-0.0038509368896484
name:-0.0081939697265625
name:-0.0013120174407959
Friedl; Arno Patent Filings

Friedl; Arno

Patent Applications and Registrations

Patent applications and USPTO patent grants for Friedl; Arno.The latest application filed is for "heterocyclically substituted imidazotriazines".

Company Profile
0.8.6
  • Friedl; Arno - Bergisch Gladbach DE
  • Friedl; Arno - Gladbach DE
*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.
Patent Activity
PatentDate
Substituted imidazotriazines
Grant 7,202,243 - Hendrix , et al. April 10, 2
2007-04-10
Substituted imidazotriazines
App 20060166993 - Hendrix; Martin ;   et al.
2006-07-27
Heterocyclically substituted imidazotriazines
App 20060166992 - Hendrix; Martin ;   et al.
2006-07-27
Imidazotriazines for use as phosphodiesterase inhibitors
Grant 6,936,609 - Erguden , et al. August 30, 2
2005-08-30
Imidazotriazines for use as phosphodiesterase inhibitors
App 20040249148 - Erguden, Jens-Kerim ;   et al.
2004-12-09
Arylsulphonamides and analogues
Grant 6,727,279 - Mittendorf , et al. April 27, 2
2004-04-27
Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases
Grant 6,573,278 - Mittendorf , et al. June 3, 2
2003-06-03
Novel arylsulphonamides and analogues
App 20030073727 - Mittendorf, Joachim ;   et al.
2003-04-17
Aryl sulphonamide amino acid esters and analogues
Grant 6,545,050 - Mittendorf , et al. April 8, 2
2003-04-08
Aryl sulphonamides and analogues
Grant 6,469,054 - Mittendorf , et al. October 22, 2
2002-10-22
Arylsulfonamides and analogues
App 20020072529 - Mittendorf, Joachim ;   et al.
2002-06-13
Use of known agonists of the central cannabinoid receptor CB1
App 20010034344 - Mittendorf, Joachim ;   et al.
2001-10-25
Use of known agonists of the central cannabinoid receptor CB1
Grant 6,284,788 - Mittendorf , et al. September 4, 2
2001-09-04
Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases
Grant 6,262,112 - Mittendorf , et al. July 17, 2
2001-07-17

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed